Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades

• Published in: Journal of antimicrobial chemotherapy Vol. 70; no. 11; pp. 3080 - 3086
• Main Authors: Doyle, Tomas, Dunn, David T., Ceccherini-Silberstein, Francesca, De Mendoza, Carmen, Garcia, Frederico, Smit, Erasmus, Fearnhill, Esther, Marcelin, Anne-Genevieve, Martinez-Picado, Javier, Kaiser, Rolf, Geretti, Anna Maria
• Format: Journal Article
• Language: English
• Published: England Oxford Publishing Limited (England) 01.11.2015; Oxford University Press
• Subjects: Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; Cohort Studies; Drug resistance; Drug Resistance, Viral; Europe; Genotype; Genotype & phenotype; HIV; HIV Infections - drug therapy; HIV Infections - virology; HIV-1 - classification; HIV-1 - genetics; HIV-1 - isolation & purification; Human immunodeficiency virus; Human immunodeficiency virus 1; Humans; Inhibitor drugs; Integrase Inhibitors - pharmacology; Integrase Inhibitors - therapeutic use; Mutation; Mutation, Missense; Original Research; Raltegravir Potassium - pharmacology; Raltegravir Potassium - therapeutic use; Europe

The aim of this study was to characterize the prevalence and patterns of genotypic integrase inhibitor (INI) resistance in relation to HIV-1 clade. The cohort comprised 533 INI-naive subjects and 255 raltegravir recipients with viraemia who underwent integrase sequencing in routine care across Europ...